Role of pharmacogenomics in the treatment of tuberculosis: a review
Open Access
- 1 September 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Pharmacogenomics and Personalized Medicine
- Vol. 5, 89-98
- https://doi.org/10.2147/PGPM.S15454
Abstract
Background: Tuberculosis is one of the major public health problems worldwide. Modern antituberculous treatment can cure most patients; cure rates > 95% are achieved with standard short-course chemotherapy regimens containing isoniazid, rifampicin, pyrazinamide, and ethambutol among patients with drug-susceptible strains of tuberculosis; however, a small proportion do not respond to treatment or develop serious adverse events. Pharmacogenomic studies of drugs used in the treatment of tuberculosis could help us understand intersubject variations in treatment response. In this review, we compiled pharmacogenomic data on antituberculous drugs that were available from different settings that would give a better insight into the role of pharmacogenomics in the treatment of tuberculosis, thereby enhancing the efficacy and limiting the toxicity of existing antituberculosis medications. Methods: The PubMed database was searched from 1960 to the present using the keywords "tuberculosis", "antituberculosis treatment", "isoniazid", "rifampicin", "pyrazinamide", "ethambutol", "pharmacogenomics", and "polymorphism". Abstracts from meetings and review articles were included. Conclusion: Studies conducted in different settings suggest that pharmacogenomics plays a significant role in isoniazid metabolism, and impacts both treatment efficacy and frequency of adverse reactions. Single nucleotide polymorphisms influencing plasma rifampicin concentrations are also reported. No data are available regarding other first-line drugs, ie, ethambutol and pyrazinamide. There is a need to incorporate pharmacogenomics into clinical trials of tuberculosis in order to understand the factors impacting therapeutic success and occurrence of adverse drug effects.Keywords
This publication has 65 references indexed in Scilit:
- The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing ImplicationsAntimicrobial Agents and Chemotherapy, 2011
- Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patientsBritish Journal of Clinical Pharmacology, 2011
- In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin ConcentrationsAntimicrobial Agents and Chemotherapy, 2010
- Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patientsJournal of Gastroenterology and Hepatology, 2006
- Isoniazid treatment of children: can genetics help guide treatment?Archives of Disease in Childhood, 2005
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- Pharmacokinetics of isoniazid metabolism in manJournal of Pharmacokinetics and Biopharmaceutics, 1976
- A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosisTubercle, 1973
- THE FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVELThe Lancet, 1956